US Pharma MarketingExclusive: UCSF spinout nets $9.1M to test virus therapy for brain cancer in China
UCSF spinout Kopra Bio has raised $9.1M to inject a genetically engineered virus into glioblastoma patients in a China trial. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Glioblastoma is notoriously good at evading the immune system, making it particularly resistant to immunotherapy, but now researchers may have found a clever workaround.
Scientists at the University of California, San Francisco ...
Source: Endpoints News